Search results for "ulcerative colitis"

showing 10 items of 237 documents

Clinical course of ulcerative colitis

2008

. Dig Liver Dis. 2008 Jul;40 Suppl 2:S247-52. Clinical course of ulcerative colitis. Cottone M, Scimeca D, Mocciaro F, Civitavecchia G, Perricone G, Orlando A. Department of Medicine, Pneumology and Nutrition Clinic, V. Cervello Hospital, University of Palermo, Palermo, Italy. AIM: To provide a review of studies on prognosis in ulcerative colitis by reviewing the relevant population-based cohort studies. On the basis of incidence and population studies, ulcerative colitis has a favourable clinical course, with good quality of life, a chronic course characterized by at least one relapse, and a surgery rate of 30% after 10 years from diagnosis. Patients affected by severe ulcerative colitis h…

medicine.medical_specialtyLymphomaColorectal cancermedicine.medical_treatmentPopulationSeverity of Illness IndexGastroenterologyRisk FactorsInternal medicinemedicineHumansColitiseducationColectomyColectomyeducation.field_of_studyHepatologybusiness.industryMortality rateGastroenterologyCase-control studyPrognosismedicine.diseaseUlcerative colitisCase-Control StudiesColonic NeoplasmsColitis UlcerativeSteroidsbusinessulcerative colittis.clinical course.Immunosuppressive AgentsCohort study
researchProduct

Therapeutic alternatives in the management of osteoradionecrosis of the jaws. Systematic review

2020

Background to systematically review the literature, comparing the healing of osteoradionecrosis (ORN) among the therapeutic alternatives: surgical, pharmacological and combined. Material and Methods The review was organized according to the PRISMA protocol with regards to the following PICO question: patients with ORN of the jaws (P=Patient); all interventions reported (I = intervention); between all therapies (C=Comparison); healing of lesions (O=outcome). Results Surgical treatment was the most common choice (46.3%) followed by pharmacological treatment, exclusively (25.9%) or combined (26.9%). Treatment exclusively by surgical intervention seems to be most effective option, with 51.2% of…

medicine.medical_specialtyOsteoradionecrosismedicine.medical_treatmentPsychological interventionMEDLINEcrohn?s diseaseReviewPharmacological treatment03 medical and health sciences0302 clinical medicineinflammatory bowel diseaseIntervention (counseling)medicineHumansSurgical treatmentGeneral DentistryLow level laser therapyUNESCO:CIENCIAS MÉDICASulcerative colitisbusiness.industry030206 dentistryapical periodontitisPrognosismedicine.diseaseSurgeryJawOsteoradionecrosisOtorhinolaryngologyHead and Neck Neoplasmstoot canal treatmentSurgeryOral SurgerybusinessJaw Diseases
researchProduct

P621 Efficacy and safety of golimumab in ulcerative colitis. Preliminary data from a multicenter Italian study

2017

medicine.medical_specialtyPancolitisTumor necrosis factorsbusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisGolimumab03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemedicine030211 gastroenterology & hepatologyPredictor variableColitismedicine.symptombusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Randomized Controlled Clinical Trials in Mild-Moderate Ulcerative Colitis

2012

The Authors review and critically discuss the most recent published evidence on treatment of mild-moderate ulcerative colitis both in the induction and maintenance of remission. Evidence on each drug is introduced by the related statement of ECCO guidelines. A brief introduction on disease classification and the need of standardizing indexes of clinical and endoscopic activity is also provided. Concluding remarks stress the heterogeneity of available studies both in the selection of patients and the outcomes evaluated and suggest the development of an international consensus in setting standards which will allow studies' results to be compared and combined to produce high quality clinical r…

medicine.medical_specialtyPathologyAlternative medicineMEDLINEAdministration OralSeverity of Illness IndexRemission inductionAdministration RectalAdrenal Cortex HormonesSeverity of illnessHumansMedicineColitisIntensive care medicineRandomized Controlled Trials as TopicPharmacologybusiness.industryRemission InductionDisease classificationGeneral Medicinemedicine.diseaseUlcerative colitisSalicylatesClinical trialColitis UlcerativebusinessAlgorithmsReviews on Recent Clinical Trials
researchProduct

WITHDRAWN: Defining In Vivo Mucosal Inflammatory Activity Using Laser Scanning Confocal Endomicroscopy in Human Ulcerative Colitis

2008

This article has been withdrawn consistent with Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). The Publisher apologizes for any inconvenience this may cause.

medicine.medical_specialtyPathologyHepatologyLaser scanningbusiness.industryConfocalGastroenterologymedicine.diseaseGastroenterologyUlcerative colitisIn vivoInternal medicineEndomicroscopyMedicinebusinessGastroenterology
researchProduct

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

2010

5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in the induction and maintenance of remission of mild-to-moderate ulcerative colitis (UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. The new delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMX formulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to ther…

medicine.medical_specialtySettore MED/09 - Medicina InternaClinical BiochemistryPharmacologyPlaceboSulfasalazineInternal medicineDrug DiscoverymedicineHumansDosingColitisMesalamine5-ASA Treatment Choice Ulcerative ColitisPharmacologyClinical Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseUlcerative colitisTacrolimusRegimenMolecular MedicineColitis UlcerativeRosiglitazonebusinessmedicine.drugCurrent Drug Targets
researchProduct

Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease

2014

Many placebo controlled trials and meta-analyses evaluated the efficacy of different drugs for the treatment of inflammatory bowel disease (IBD), including immunosuppressants and biologics. Their use is indicated in moderate to severe disease in non responders to corticosteroids and in steroid-dependent patients, as induction and maintainance treatment. Infliximab, as well as cyclosporine, is considered a second line therapy in the case of severe ulcerative colitis, or non-responders to intravenous corticosteroids. An adequate dosage and duration of therapy with thiopurines should be reached before evaluating their efficacy. Methotrexate is a valid option in patients with Crohn’s disease bu…

medicine.medical_specialtySettore MED/09 - Medicina InternaCombination therapyInflammatory bowel diseaseGastroenterologyimmunosuppresantbiologicsinflammatory bowel diseaseCrohn DiseaseGastrointestinal AgentsRisk FactorsInternal medicinemedicineimmunomodulators.optimization. treatmentHumansTopic HighlightBiological ProductsGastrointestinal agentCrohn's diseaseThiopurine methyltransferasebiologybusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisTacrolimusInfliximabSurgeryTreatment Outcomebiology.proteinColitis UlcerativeDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Inflammation and Aortic Stiffness: An Individual Participant Data Meta‐Analysis in Patients With Inflammatory Bowel Disease

2017

Background The recent finding that aortic pulse wave velocity ( aPWV ) is increased in patients with inflammatory bowel disease may explain why the cardiovascular risk is increased despite the low prevalence of traditional cardiovascular risk factors. We aimed to test whether inflammation is associated with aortic stiffening in this setting after adjustment for major confounders and to perform subgroup analyses. Methods and Results A systematic literature search for aPWV in inflammatory bowel disease was performed using PubMed, Scopus, Web of Science, and Google Scholar databases (last accessed May 7, 2017). Inclusion criterion was peer‐reviewed publications on clinical studies reporting o…

medicine.medical_specialtySettore MED/09 - Medicina Internapulse wave velocitycardiovascular complicationsBlood SedimentationPulse Wave Analysis030204 cardiovascular system & hematologyStandard scoreInflammatory bowel diseaseLeukocyte Count03 medical and health sciencesVascular Stiffness0302 clinical medicineCrohn DiseaseRisk FactorsInternal medicinemedicineHumansArterial stiffness; Cardiovascular complications; Crohn's disease; Inflammation; Pulse wave velocity; Ulcerative colitis; Cardiology and Cardiovascular Medicine030212 general & internal medicineulcerative colitisInflammationSystematic Review and Meta‐AnalysisCrohn's diseasemedicine.diagnostic_testbusiness.industryMeta Analysisinflammation aortic stiffnessPrognosismedicine.diseaseUlcerative colitisConfidence intervalCrohn's diseaseC-Reactive Proteinarterial stiffnessCardiovascular DiseasesMeta-analysisErythrocyte sedimentation rateMultivariate AnalysisHypertensionLinear ModelsPhysical therapyArterial stiffnessColitis UlcerativeInflammation MediatorsCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of the American Heart Association
researchProduct

Smoking therapy may be an extreme cure in exsmokers with steroid-dependent and resistant ulcerative colitis.

2011

medicine.medical_specialtySteroid dependencySettore MED/09 - Medicina Internabusiness.industryInternal medicineSmoking therapyexsmokers steroid-dependentulcerative colitisGastroenterologymedicineImmunology and Allergymedicine.diseasebusinessUlcerative colitisGastroenterology
researchProduct

Responses to self and non-self intestinal microflora in health and inflammatory bowel disease.

1997

medicine.medical_specialtyT-LymphocytesImmunologyBiologyCross ReactionsInflammatory bowel diseaseGastroenterologyAntibodiesImmune tolerancePathogenesisMiceImmune systemCrohn DiseaseInternal medicinemedicineAnimalsHumansCrohn diseaseCross reactionsmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisInterleukin-12Interleukin-10IntestinesInterleukin 10Disease Models AnimalImmunologyForecastingResearch in immunology
researchProduct